Insilico Medicine to present on CXOTALK

Thursday, January 31, 2019 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery on a live episode of the influential CXOTalk Show on February 8, 2019 at 1:00 PM Eastern time. 

Artificial intelligence (AI) has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, get medications to patients faster and help patients comply with their treatments. 

At Insilico, AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, AI helps more drugs to be discovered and come to market quickly. The interview will focus on the latest advances in artificial intelligence for discovery, development and real world evidence collection of drugs and geroprotectors.

"We are happy to present our work on a live episode of CXOTalk. The topic of AI for Drug Discovery is rapidly gaining popularity, and we are happy to be at the leading edge of research and one of the innovation drivers in the area", says Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.

Industry analyst and host of CXOTalk, Michael Krigsman, said, "Dr. Zhavoronkov and Insilico are prominent voices in using AI for drug discovery. We are excited to discuss this important topic with Alex."

CXOTalk offers in-depth discussions and interviews on disruption and transformation with the world's most innovative leaders in business and technology, since 2013. Topics include AI, data science, digital transformation, and evolving business models. 

The event will go live on the 8th of February 2019, at 1 PM ET.

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging researchincluding the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field. 

###

For further information, images or interviews, please contact:

Contact: Polina Firsanova 
ai@pharma.ai

Website: http://insilico.com/

CXOTalk Official Website : https://www.cxotalk.com/

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com

Insilico to present its latest research in AI aging clocks at the Longevity Leaders Conference

Thursday, January 24, 2019 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in human aging biomarker development at the Longevity Leaders Conference in London, 4 of February.

Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in studying the biology of aging on many levels. The panel discussion will focus on the new frontiers in the biology of aging and the future of longevity science. Another major point of discussion is how technology and industry collaborations can drive successful outcomes in longevity science.

"We are happy to present our latest research at the Longevity Leaders Conference, which gathers the leading longevity scientists and investors. The topic of AI for Aging research and Productive longevity is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area", says Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.

The Longevity Leaders Conference brings together key opinion leaders, CEOs, innovators and disruptors from the world of life sciences, technology, financial services, government and the investment community, to discuss how the grand challenges of Longevity can be tackled, how the significant opportunities can be seized, and to forge the partnerships and relationships to succeed in this new age. The Longevity Leaders Conference is held on February 4 in London. 

###

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging researchincluding the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field. 

For further information, images or interviews, please contact:

Contact: Ola Popova 
ai@pharma.ai 
Website: http://insilico.com/ 
Official website of the conference: https://www.lsxleaders.com/longevity-leaders-congress

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com

Insilico to present latest advances in AI for drug discovery at R&D Data Intelligence Leaders Forum

Thursday, January 17, 2019 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at the R&D Data Intelligence Leaders Forum in Basel, Switzerland, 24 of January.

Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in making the hunt for new pharmaceuticals quicker and more effective. At Insilico AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, AI helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for discovery, development and real world evidence collection of drugs and geroprotectors.

"We are happy to present our work at the R&D Data Intelligence Leaders Forum, which gathers the key industry leaders. The topic of Next-Generation AI for Drug Discovery is rapidly gaining popularity, and we are happy to be at the leading edge of research and one of the innovation drivers in the area", says Alex Zhebrak, Chief Technology Officer at Insilico Medicine, Inc.

The 6th Annual Life Science R&D Data Intelligence Leaders Forum The "R&D Data Intelligence Leaders Forum" is the must attend event for the senior decision-makers, researchers and technologists, looking to make the shift towards an integrated R&D and data strategy and for those looking to improve their implementation of data-driven approaches to enhance R&D decision-making and intelligence. The Forum is held on 23-25 of January in Basel, Switzerland.

###

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging researchincluding the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field. 

For further information, images or interviews, please contact:

Contact: Polina Firsanova

ai@pharma.ai

Website: http://insilico.com/

Official website of the conference: 

https://www.nextlevells.com/events/r-d-data-intelligence-leaders-forum-2019

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com

Insilico and Elevian enter a research collaboration to discover drugs that target aging

Two longevity biotechnology companies partner to discover drugs that target aging

Jan. 9, 2019, San Francisco, CA - On the final day of the largest biotechnology and pharmaceutical partnering week at the Juvenescence Longevity Showcase two leading longevity biotechnology companies, Elevian and Insilico Medicine announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets. Elevian is an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent the diseases of aging. Its first target is the GDF11 pathway. Insilico Medicine is an Artificial Intelligence (AI) company developing an end-to-end pipeline for automated target identification, small molecule generation, prediction of clinical trials outcomes and aging research. It is a leader in the fields of deep learning for drug discovery, biomarker development, and anti-aging interventions. The collaboration will take advantage of Insilico's generative adversarial networks (GANs) and reinforcement learning (RL) AI technologies to discover novel small molecules that target the GDF11 pathway, which has been demonstrated to play an important role in aging and age-related disease.

"We are excited to partner with Insilico Medicine," said Mark Allen, MD, CEO of Elevian. "Not only will we leverage Insilico's advanced AI technology to accelerate drug development, but we also share a common mission: to eliminate age-related disease and promote healthy longevity."

"We are looking forward to working with Elevian. GDF11 is an exciting pathway and Elevian's scientists are world leaders in this field coming from Harvard and other prestigious institutions. Their management has a solid vision and is committed to doing great research and turn it into the life-saving products in record time," said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine

In order to succeed in this endeavor, the companies will utilize state of the art techniques in AI-enabled drug discovery. Based on biological and structural target data from Elevian, Insilico will identify small molecules that produce the intended biological actions utilizing deep learning technology. Starting out with existing libraries of compounds and molecular building blocks, based upon iterations of virtual and biological screenings, the scientists will narrow down the list of potential candidates. Subsequently, based on the results of previous iterations, Insilico will also provide a selection of novel de novo compound candidates, which will be synthesized by WuXi AppTec, a leading global pharmaceutical contract research and manufacturing organization. Using this approach, Insilico and WuXi have recently discovered novel small molecules for challenging targets.

"My fund, BOLD Capital Partners, is a proud investor in both Elevian and Insilico. This partnership perfectly illustrates the convergence of biotechnology and AI, which together are shaping the future health of humanity," said Peter Diamandis, MD, Founder and Chairman of the XPRIZE Foundation and Partner at BOLD Capital Partners.

"We are in the middle of a biotechnology revolution," said Jim Mellon, Chairman of Juvenescence Limited and investor in Insilico Medicine. "Within most people's lifetimes, the developments in the longevity biotechnology sector will allow us to live increasingly long and healthy lives, and provide one of the best investment opportunities ever."

###

About Insilico Medicine, Inc. 

Insilico Medicine is an artificial intelligence company with R&D offices and resources in the US, Belgium, Russia, the UK, Taiwan, and Korea, sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for diseases with a known ligand and with no known targets. In addition to working collaborations with large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products, compounded using advanced bioinformatics and deep learning techniques. It also provides a range of consumer-facing applications, including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies for potential in social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied by industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. 

http://www.insilico.com

About Elevian, Inc.

Elevian is an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent the diseases of aging. Elevian's scientific founders, working at the Harvard Department of Stem Cell and Regenerative Biology, discovered that replenishing the circulating factor GDF11 can regenerate the heart, brain, muscle and other tissues. Elevian has acquired exclusive, worldwide rights to Harvard's patent portfolio concerning circulating factors that regulate aging. The company is developing new medicines that target the GDF11 pathway. Elevian's lead drug candidate (recombinant human GDF11) has demonstrated efficacy in preclinical models of heart failure, Alzheimer's disease, stroke, Type 2 diabetes, and age-related muscle dysfunction. The company has also established additional programs focused on the discovery and development of novel proteins, antibodies and small molecule drugs that target the GDF11 pathway. 

http://www.elevian.com

TARA Biosystems and Insilico Medicine announce collaboration for cardiac disease

Rockville, Maryland, Monday, January 7, 2019 - Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines for age-related diseases and TARA Biosystems, Inc. a company offering "heart-on-a-chip" tissue models for drug discovery and risk assessment applications, announced today the launch of a collaboration to discover and develop novel therapies for cardiac disease and diseases associated with cardiac muscle aging. 

The discovery and development of new drugs for cardiac disease requires significant time and capital. The unique collaboration will address this significant global health problem by combining Insilico Medicine's rapid discovery capabilities with the power of TARA's human-relevant tissue models, shaving off years and associated expense and incorporating clinically-relevant physiology early and consistently throughout preclinical development.

"At TARA, we engineer human cardiac tissue to mimic specific human disease phenotypes which are used to validate novel targets and rapidly evaluate new compounds for positive effects on cardiac function. Partnering with Insilico Medicine further maximizes TARA's cardiac drug discovery platform," states Misti Ushio, PhD, CEO of TARA Biosystems. "We feel privileged to be working with Insilico Medicine and have been duly impressed by their technical, scientific and business expertise."

"At Insilico Medicine, we interrogate hundreds of disease-relevant assays on a regular basis to identify those biological systems that we can trust to validate the targets and molecules identified using our end-to-end drug discovery pipelines. TARA's cardiac tissue models are the next best thing to a human heart. Serendipitously, they have one of the most professional and agile management teams that we have encountered during our quest for the best assays. This kind of partnership between AI companies and engineered biology companies is very new and we are extremely excited to partner with TARA Biosystems, a team with a good heart," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine.

###

About TARA Biosystems, Inc.

TARA Biosystems, Inc. provides predictive, in vitro human cardiac tissue models for use in drug discovery and risk assessment. TARA Biosystems offers a high-fidelity solution that is based on human iPSC derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The TARA platform allows pharma to access human cardiac information on therapeutics candidates earlier in the drug development cycle. In 2018, TARA Biosystems received Frost & Sullivan's prestigious North American Technology Innovation Award for its trailblazing Biowire™ II heart-on-a-chip platform.

About Insilico Medicine, Inc.

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. Insilico Medicine is one of the founding companies of the Alliance of Artificial Intelligence in Healthcare (AAIH).

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com

Contacts:

For further information, images or interviews, please contact:

Donna See 
TARA Biosystems, Inc. 
917-512-3037 
donna@tarabiosystems.com 
http://www.tarabiosystems.com

Polina Firsanova 
Insilico Medicine, Inc. 
ai@pharma.ai 
http://insilico.com/